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Abstract
Background: Inflammatory reactions, known to promote tumor growth and invasion, have been found associated with
colorectal carcinoma (CRC). Macrophages are the chief component of the inflammatory infiltration that occurs early in the
progression from non-invasive to malignant tumor, with a switch from the pro-inflammatory phenotype to the tumor-
promoting phenotype. Tumor and stroma are additional sources of inflammation-related molecules. The study aimed to
evaluate, during colorectal carcinogenesis from benign to malignant phases: i) the trend of serum levels of IL-8, IL-6, TGFb1,
VEGF and MMPs; ii) the parallel trend of CRP serum levels; iii) derangement of the principal TGFb1 receptors (TGFb1RI/RII) in
tumor tissues.
Methodology/Principal findings: 96 patients with colon adenomas or CRC at different stages of progression, and 17
controls, were recruited. Serum IL-8, IL-6, TGFb1, VEGF, MMPs and CRP levels were analyzed before endoscopy or surgery.
TGFb1 receptors were evaluated in adenoma biopsies and surgically-removed colorectal adenocarcinomas. Serum levels of
IL-8 in adenocarcinoma patients were increased from stage II, when also the enzymatic activity of MMP-9 increased. Of note,
the increasing trend of the two serum markers was found significantly correlated. Trend of serum CRP was also very similar
to that of IL-8 and MMP-9, but just below statistical significance. TGFb1 levels were lower at stage III CRC, while IL-6 and
VEGF levels had no significant variations. In tissue specimens, TGFb1 receptors were already absent in about 50% of
adenomas, and this percentage of missing receptors markedly increased in CRC stages III and IV.
Conclusions: Combined quantification of serum IL-8, MMP-9 and CRP, appears a reliable and advanced index of
inflammation-related processes during malignant phase of colorectal carcinogenesis, since these molecules remain within
normal range in colorectal adenoma bearing patients, while consistently increase in the blood of CRC patients, even if from
stage II only.
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Introduction
Colorectal carcinoma (CRC) is one of the most common
malignant tumors worldwide, with one million new cases
diagnosed each year. Almost 60% of cases occur in developed
countries, and in Europe it is the second cause of cancer-related
death [1–3]. CRC may develop from adenomatous polyps
(adenomas), the precursor lesions, whose malignant potential
depends on their size, morphology, and grade of dysplasia [4]. The
fact that this type of malignant tumor commonly arises from
adenomatous polyps has been proven in the case of hereditary
colon cancer syndromes, which may carry up to 100% risk of
carcinoma, as in familial adenomatous polyposis [5].
In the last few years, the role of inflammation in the initiation
and progression of colorectal carcinoma has been investigated in
greater depth. Inflammatory reactions are associated with almost
all types of malignant tumors, and are known to promote tumor
proliferation, angiogenesis and metastasis, and to increase re-
sistance to hormonal or chemo-therapies. Monocyte/macrophage
cells are usually the major component of the inflammatory
infiltrate in the microenvironment of most malignant tumors; they
are thus called tumor-associated macrophages (TAM). Phagocyte
infiltration begins early in the non-invasive stage of the tumor, and
continues progressively with an evident but gradual switch from
the M1 pro-inflammatory phenotype to the M2 cancer-promoting
phenotype. This event directly influences behavior and function of
tumor cells, and promotes tissue remodeling and repair,
immunomodulation, angiogenesis, and tumor progression [6].
Notably, colorectal cancer cells, stimulated by preexisting inflam-
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mation, or driven by intrinsic pathways related to gene defects,
may also secrete different cytokines, and activate the local stromal
cells to do likewise [7].
Among the cytokines involved in inflammation-associated
intestinal tumorigenesis, an important role is played by in-
terleukin-6 (IL-6) and interleukin-8 (IL-8). Both have been found
over-expressed in CRC with increased angiogenic and metastatic
potential [8]. The IL-6 and IL-8-dependent inflammatory network
appears to significantly contribute to relating oncogene-induced
cellular senescence with an inflammatory phenotype and tumor
progression [9].
Other inflammation-related molecules, such as transforming
growth factor b1 (TGFb1), vascular endothelial growth factor
(VEGF) and matrix metalloproteases (MMPs), become predomi-
nant during advanced tumor stages [6]. TGFb1 is an important
cytokine, which probably plays a major role in the association of
inflammation and carcinogenesis. Under physiological conditions,
this pleiotropic peptide is involved in regulating cell processes
including proliferation, survival, differentiation and apoptosis:
TGFb1 inhibits the growth of epithelial cells, including intestinal
epithelial cells, by enhancing differentiation and apoptotic path-
ways, while it promotes the proliferation of fibroblasts and
myofibroblasts, as well as the deposition of extracellular matrix
[10]. Further, TGFb1 is an extremely potent immunosuppressive
factor that inhibits proliferation, activation and differentiation of
immune effector cells, thus its over-expression might contribute to
promoting the invasive and metastatic behavior of tumor cells
[11]. Indeed, in a previous study on a series of colorectal cancers,
at different stages, from I to IV, the amount of TGFb1 was found
significantly increased only in the most advanced cancer stage
[12].
Derangement of the TGFb1 signal transduction pathway,
mediated by mutations or polymorphisms of its receptors and/or
of the transduction molecules, SMADs, is considered to play
a primary role in the development and progression of several types
of cancer in humans [13,14]. In addition, the derangement of
TGFb1 receptors, TGFb1RI or TGFb1RII, can contribute to
colon cancer formation and metastasis [15]. Our previous
experience with a series of 15 patients, who had undergone
CRC surgical resection, led to the observation of a significant
reduction of TGFb1RI (7/15) and TGFb1RII (3/15) in the tumor
mass versus the apparently normal surrounding colonic mucosa
[12]. Further, mutations in the TGFb1RII are estimated to occur
in approximately 30% of CRC [15,16].
On the basis of the current literature, sufficient data are now
available concerning TGFb1RI and TGFb1RII changes in
established CRC, but the trend of these molecules during the
early phases of carcinogenesis, i.e. in benign tumors of the
colorectum, remains to be defined.
VEGF has emerged as a critical mediator of angiogenesis,
required for invasive tumor growth and metastasis and, therefore,
targeted antibodies against VEGF and its receptors have been
introduced as potential antitumor therapy [17–19]. Inflammatory
cytokines themselves are potent activators of MMPs, enzymes that
demolish extracellular matrix proteins and that are likely involved
in all steps of colorectal carcinogenesis. However, notwithstanding
their likely involvement in this process, the available data do not
elucidate the actual trend of their serum levels during both benign
and malignant phases of colorectal carcinogenesis [20]. The same
applies to the levels of here investigated cytokines, which are
considered as macrophage markers of phenotypes 1 and 2 by
Mantovani and co-workers [21].
In this paper, a comprehensive group of patients affected by
either benign (adenomas) or malignant (adenocarcinomas) co-
lorectal tumors at different stages was investigated. The goal was: i)
to define the trend of serum levels of IL-8, IL-6, TGFb1, VEGF
and MMPs, throughout the entire manifest process of colorectal
carcinogenesis; ii) to compare the trend of the inflammatory
cytokines IL-8 and IL-6 with that of C-reactive protein (CRP); iii)
to characterize fully the behavior of TGFb1RI and TGFb1RII in




The study population comprised 96 patients affected by colonic
adenoma or colorectal carcinoma, recruited at San Luigi Gonzaga
University Hospital (Orbassano, Turin, Italy) between November
2008 and November 2010. Twenty-eight adenomas were endo-
scopically removed at the Division of Gastroenterology (9 women,
19 men, age range 47 to 79, median age 68 years). Sixty-eight
CRC patients (31 women, 37 men, age range 46 to 80 years,
median age 73) received surgery at the Division of General
Surgery.
Of the colonic adenomas, based on the presence of villous
structure, 11 were histologically classified as tubular adenomas
(less than 20% of the tumor mass with villous structure) and 17 as
tubulovillous adenomas (between 20 and 80% of the tumor mass
with villous structure). Of the CRC patients, 11 were classified as
stage I adenocarcinoma, 25 as stage II adenocarcinoma, 26 as
stage III adenocarcinoma and 6 patients as stage IV adenocar-
cinoma, according to the TNM staging system. Patients were
excluded from the study if they were aged above 80 or below
40 years, if they had associated chronic inflammatory diseases
and/or previous surgical intervention on the intestine, or if they
had received radiotherapy or chemotherapy before surgery.
Seventeen healthy blood donors were selected as control group.
The study protocol, in agreement with the ethical guidelines of
the 1975 Declaration of Helsinki, was approved by the local
Ethical Committee (San Luigi Hospital, Orbassano, Italy, n. 191/
INT) and written informed consent was obtained from each
patient enrolled.
Tissue Samples
Both adenoma biopsies and surgically-removed segments of
CRC were fixed in 4% formaldehyde and embedded in paraffin
for standard histological (hematoxylin-eosin staining) and immu-
nohistochemical analyses.
Blood Serum Samples
Blood specimens were taken from patients one day before
surgical resection of the tumor mass, and on the day of the
colorectoscopic procedure. The samples were collected in plain
glass tubes and the serum was immediately separated by
centrifugation (2000 g) then stored at 280uC, ready for analyses.
In the control group, blood sampling, processing and storage were
performed similarly.
Detection of Inflammatory Molecules in Serum
Inflammatory molecules were detected using ELISA standard
protocols and following the manufacturer’s instructions (ELISA
ImmunoTools kit, Germany, for IL-6 evaluation; Instant ELISA
kit, Bender Med System, Prodotti Gianni, Milan, Italy, for IL-8
evaluation; DuoSet ELISA kit, R&D Systems, UK, for TGFb1,
MMP-9 and VEGF165,121,165b analyses). A 96-well microtiter plate
reader (Model 680 Microplate Reader, Bio-Rad, Milan, Italy) was
used to detect each molecule, and serum levels were calculated
IL-8 and MMP-9 in Colorectal Carcinogenesis
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using the software SlideWrite (Advanced Graphics Software, CA,
USA). IL-6, IL-8 and VEGF were expressed as pg/ml serum;
TGFb1 and MMP-9 were expressed as ng/ml serum.
C-reactive Protein (CRP) Analysis
CRP was detected in the serum using a latex immunoassay. The
CRP concentration was quantified by turbidimetry and the
absorbance change was detected at 572 nm wavelength (Architect
c System Analyzer, Abbott Diagnostics, Abbott Park, IL, USA).
Serum levels of the protein were expressed in mg/L.
Gelatin Zymography
MMP-2 and MMP-9 activities in serum samples were assayed
by gel zymography. Proteins (100 mg) were separated by
electrophoresis in 8% SDS-PAGE gel containing gelatin
(0.8 mg/ml) under non-reducing conditions. The gel was washed
with Tris buffer (2.5% Triton X-100 in 50 mM Tris-HCl, pH 7.5,
final solution) for 1 hour and then incubated overnight at 37uC in
a proteolysis buffer (40 mM Tris-HCl, 200 mM NaCl, 10 mM
CaCl2, 0.02% NaN3, pH 7.5, final solution). The gel was then
stained for 3 hours with Coomassie Blue solution (0.05%
Coomassie Brilliant Blue R-250, 50% methanol, 10% acetic acid,
final solution) and finally destained with 5% methanol and 7%
acetic acid (final solution). Reagents and chemicals were from
Sigma–Aldrich (Milan, Italy) and VWR International (Milan,
Italy). MMP-9 activity was detected as a clear band on a blue
background and estimated by densitometric analysis using Image J
Software (USA). The results were expressed as percentages of
control values.
Immunohistochemical Analyses
TGFb1RI, TGFb1RII were tested on tumor tissue sections
from all patients. Paraffin-embedded tissue was deparaffinized and
rehydrated through graded alcohols. Heat-induced antigen re-
trieval was performed by microwave treatment in citrate buffer
(pH 6.0) three times for 5 minutes, followed by cooling for
30 minutes at room temperature. Endogenous peroxidase activity
was quenched by a 15 minute treatment with 3% hydrogen
peroxide. Following 15 minute incubation in bovine serum in
Tris-Buffered Saline (TBS)/Tween-20 solution, sections were
incubated overnight in a humidified chamber at 4uC in the
presence of specific polyclonal mouse antibodies (8 mg/ml anti-
TGFb1RI, 4 mg/ml anti-TGFb1RII, Santa Cruz, Tebu-Bio s.r.l.,
Magenta, Milan, Italy). After washing with TBS, slides were
incubated for 35 minutes with secondary anti-mouse antibodies
(Dako, Glostrup, Denmark). The immune reaction was then
revealed with EnVision System-HRP using diaminobenzidine as
chromogen (Dako, Glostrup, Denmark). Sections were finally
counterstained with hematoxylin, dehydrated through graded
alcohols, mounted and examined at a Leica microscope (Leica
Microsystems Wetzlar GmbH, Wetzlar, Germany). The staining
intensity was evaluated by two independent observers, in random
order, at 20x and 100x magnifications. Semiquantitative analysis
was expressed as minimal, low, medium or high grade immunos-
taining as follows: the score was calculated as percentage of
positive stained cells multiplied by corresponding staining in-
tensity. This procedure determined a score of up to 12 points,
which were categorized as minimal (score 1–3); low (score 4–6);
medium (score 7–9) and high (score 10–12) reactivity.
In a limited number of sections from stage III colorectal cancers,
the distribution of MMP-9 and IL-8 within the tumor mass was
investigated. For this purpose, sections were incubated overnight
in the presence of either 0.5 mg/ml anti IL-8 or 1 mg/ml anti
MMP-9. The remaining technical procedure was the same as for
immunohistochemical detection of TGFb1 receptors (see above).
The objectives used were 10x/0.22 and 40x/0.65.
Statistical Analyses
Results were expressed as Mean 6 Standard Error of the Mean
(SEM). Statistical differences between groups were evaluated using
Student’s t-test and one-way ANOVA test associated with the
Bonferroni’s multiple comparison post test. To determine the
degree of correlation among different serum variables of each
patient within any single tumor group, non parametric Spear-
man’s test was performed. All data were analyzed with GraphPad
InStat software (San Diego, USA).
Results
Serum Levels of IL-8, IL-6 and CRP in Patients Bearing
Tubular or Tubulovillous Colorectal Adenoma or
Adenocarcinoma at Different Stages of Progression
Figure 1 shows levels of IL-8 and IL-6, as markers of the pro-
inflammatory macrophage phenotype, in the peripheral blood of
patients undergoing endoscopic or surgical resection, of colorectal
adenoma or adenocarcinoma, respectively. IL-8 serum levels
remained within the control range in patients affected by colonic
tubular or tubulovillous adenoma. The IL-8 level then began to
rise in stage I CRC patients, showing a statistically significant
increase in those with cancer at stages II and III, i.e. the two
largest groups under investigation (Figure 1A). Unlike IL-8, serum
levels of IL-6 in tumor-bearing patients did not show any
significant changes versus controls, although a modest but
inconsistent increase was observed at cancer stages II and III
(Figure 1B). Notably, in the same cohort of patients, CRP, i.e. the
most commonly used inflammatory marker, showed a trend quite
similar to that of IL-8, with normal serum levels in patients with
benign colorectal tumors, and an increase starting from stage II of
malignancy, but just below statistical significance (Figure 2).
Serum Levels of TGFb1 and VEGF in Patients Bearing
Tubular or Tubulovillous Colorectal Adenoma or
Adenocarcinoma at Different Stages of Progression
In the same cohort of oncologic patients and healthy controls,
the serum concentrations of TGFb1 and VEGF, were determined.
The mean serum levels of the pleiotropic cytokine TGFb1,
measured in patients with either tubular or tubulovillous colorectal
adenomas, as well as in patients with stage I adenocarcinoma, did
not show any significant variation versus controls. The TGFb1
serum levels decreased at stages II and III adenocarcinomas,
although only at stage III adenocarcinoma a significant difference
was achieved versus controls (Figure 3A).
Conversely, there was no evident variation in VEGF levels in
the peripheral blood of controls versus patients affected by either
adenomas or adenocarcinomas, although a slight but not
significant increase was observed at advanced stages of adenocar-
cinoma (Figure 3B).
Immunohistochemical Analysis of TGFb1RI and TGFb1RII
in Specimens of Tubular or Tubulovillous Colorectal
Adenoma or Adenocarcinoma at Different Stages of
Progression
As there is considerable evidence suggesting that tumor cells
may become not responsive to TGFb1-dependent cell signaling,
the levels and distribution of the two main receptors of TGFb1
were analyzed in histological tissue sections of adenomas and
adenocarcinomas. Semi-quantitative analyses were performed,
IL-8 and MMP-9 in Colorectal Carcinogenesis
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applying a commonly-used immunostaining score. Peritumoral
colonic mucosa had a uniform staining for both TGFb1RI and
TGFb1RII. Unexpectedly, at the early steps of colorectal
carcinogenesis, i.e. in tubular and tubulovillous adenomas, the
amount of RI and RII receptors expressed by the neoplastic cells
was below that of normal mucosa in about 50% of the specimens
examined, with one or both receptors reduced in each tumor
specimen. Quite similar results were obtained for TGFb1RI and/
or TGFb1RII levels in stage I and II adenocarcinomas, with
decreased receptor levels in 60% and 56% of the cases,
respectively. At the more advanced stages of colorectal cancer
progression, expression of TGFb1 receptors in tumor tissue
showed a clear-cut decrease in the vast majority of stage III and
in all stage IV adenocarcinomas (Table 1).
Figure 1. Evaluation of serum levels of IL-8 and IL-6 during colorectal carcinogenesis. The levels of IL-8 (A) and IL-6 (B) were measured in
controls and patient groups (N: control; TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma). IL-8 and IL-
6 were detected by ELISA and values expressed as pg/ml serum (see materials and methods). A: dots correspond to IL-8 single values and black lines
represent the mean values within the experimental groups. Mean values6 SEM: N 17.062.5; TA 15.963.7; TVA 18.462.2; IAC 25.464.8; IIAC 38.765.1;
IIIAC 37.265.7; IVAC 30.565.7. *Significantly different versus control group (p,0.05). B: dots correspond to single IL-6 values and black lines represent
the mean values within experimental groups. Mean values 6 SEM: N 247.1655; TA 375.9654; TVA 407.9680; IAC 237.9668; IIAC 472.3689; IIIAC
521.36152; IVAC 436.36118. *Significantly different versus control group (p,0.05).
doi:10.1371/journal.pone.0041839.g001
IL-8 and MMP-9 in Colorectal Carcinogenesis
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e41839
Metalloprotease Activity and MMP-9 Protein Levels in
Serum of Patients Bearing Tubular or Tubulovillous
Colorectal Adenoma or Adenocarcinoma at Different
Stages of Progression
The activity of both the metalloproteases principally involved in
malignant phenotype acquisition, i.e. MMP-2 and MMP-9, was
measured by zymography. While MMP-2 activity showed no
significant difference at any tumor stage (Figure 4A), the behavior
of MMP-9 was more interesting: the enzymatic activity increased
in malignant tumors, being significantly different at stages II and
III of cancer progression (Figure 4A/B).
Based on these observations, we decided to quantify serum
levels of MMP-9 as a further considered marker of type 2
monocytic activation. In line with observations for MMP-9
activity, serum protein levels showed a net and significant increase
in the malignant phases of colorectal carcinogenesis, with mean
values significantly different from controls at stage III (Figure 4C).
Notably, at this stage of progression the increase of MMP-9
significantly correlated with IL-8 serum levels (Spearman’s rank
correlation coefficient r = 0.4331, p= 0.039).
Immunohistochemical Analysis of IL-8 and MMP-9 in
Specimens of Adenocarcinoma at Advanced Stage of
Progression
Taking into account the statistically significant increase of IL-8
and MMP-9 concentrations in the peripheral blood of patients at
stage II and III adenocarcinoma, the actual distribution of these
two molecules was then verified in a limited number of
corresponding CRC sections by immunohistochemistry. While
IL-8 resulted to be expressed mainly by inflammatory cells
infiltrating the adenocarcinoma in advanced stage of progression,
and apparently not by cancer cells (data not shown), MMP-9 was
clearly produced in large amount by both macrophages and tumor
cells (Figure 5).
Discussion
This study provides a first overall picture of the trend of serum
inflammation markers, during the entire manifest phases of
colorectal carcinogenesis, namely in benign adenomas and in the
different stages of CRC. To date, relevant studies have focused on
the malignant phases of this multistep process; many have been
less than comprehensive, and have not investigated trends of
potential serum markers of inflammation and disease progression
during the expression of benign lesions, i.e. colorectal adenomas.
The proinflammatory cytokines IL-6 and IL-8 are known to be
involved in the development of colorectal cancer [22–24]. Tumor-
associated macrophages are the most likely source of these
cytokines, but colon cancer cells themselves were reported to
synthesize IL-8, under inflammatory conditions [8,25–27]. In our
study, the immunohistochemical analysis of CRC specimens did
not show significant presence of IL-8 within cancer cells or the
surrounding stroma, being the cytokine production mainly de-
pendent on the inflammatory infiltrate (data not shown). Further,
the observed trend of IL-8 levels in the peripheral blood of patients
bearing colorectal adenomas and adenocarcinomas clearly
demonstrates that the increase of this important inflammatory
mediator is limited to the malignant phase of the neoplastic disease
(Figure 1A). More precisely, serum IL-8 began to significantly
increase at stage II adenocarcinoma. Hence, although inflamma-
tory reactions were certainly triggered by the developing neoplasia
well before reaching stage II, net evidence of inflammation
occurred in the serum relatively late during the multistep process
of colon carcinogenesis, and IL-8 alone can not be taken as
a specific marker of malignancy in the neoplastic disease of
colorectum. Contrary to the behavior of IL-8, IL-6 did not show
any particular variation in the serum of cancer patients versus
healthy individuals (Figure 1B).
In parallel with these cytokines, serum levels of CRP, which is
routinely used as an inflammation marker, were analyzed. CRP
displayed a trend very similar to that of IL-8 serum levels
(Figure 2). Whereas this provides further support for the validity of
CRP as a general marker of inflammation, it also strongly suggests
that CRP analysis should be combined with that of other
inflammatory molecules, as it has already been recommended
[28]. An appropriate spectrum of inflammatory cytokines, in-
cluding IL-8, might be considered as a potential tool for
monitoring inflammation in the serum of patients with CRC.
Very recently, a multiplex-based analysis of the major
inflammatory cytokines and growth factors considered to be
potential serum markers for colon cancer pointed to IL-8 as the
only molecule of this class that might be useful for diagnosis and
disease monitoring. The inflammation-related molecules simul-
taneously quantified in 100 serum samples of colon cancer
patients (stages I to IV) were: IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-
8, IL-10, VEGF, EGF, TNFa, IFNc, MCP-1, but only IL-8
serum levels showed a statistically significant difference between
controls and adenocarcinoma patients. Further, in full agreement
with our findings, the serum IL-8 increase was evident at stages
II, III, IV of colorectal cancer, while in the blood of patients with
stage I adenocarcinoma it was still within the control range [29].
None of the other cytokines and growth factors tested
discriminated between controls and cancer patients. In this
context, mean serum VEGF values increased in cancer patients
versus controls, but the study failed to find any statistical
significance [29].
The participation of angiogenesis in the later phases of
colorectal tumor progression has been widely described, and
connections have been reported between the levels of VEGF
Figure 2. Evaluation of serum levels of CRP during colorectal
carcinogenesis. The levels of CRP were measured in controls and
patient groups (N: control; TA: tubular adenoma; TVA: tubulovillous
adenoma; I-IV AC: malignant stages of adenocarcinoma). CRP was
detected by latex immunoassay analysis and expressed as mg/L serum
(see materials and methods). Dots correspond to single CRP values and
black lines represent the mean values within the experimental groups.
Mean values 6 SEM: N 3.560.1; TA 3.760.7; TVA 5.761.1; IAC 7.561.8;
IIAC 24.368.5; IIIAC 27.967.5; IVAC 17.264.1.
doi:10.1371/journal.pone.0041839.g002
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expression and tumor invasivity and aggressiveness [30–32].
However, in our series of patients, mean serum VEGF levels
showed no significant change during the progression from benign
to malignant colorectal neoplastic disease, probably because our
data were more widely dispersed. In addition, the small number of
patients at the advanced stage of CRC is a limiting factor in our
study (Figure 3B).
As regards TGFb1 serum levels, a negative trend was observed
at stages II and III adenocarcinomas, with a significant difference
only at stage III (Figure 3A). According to the theory now widely
recognized, loss of susceptibility to the differentiating and pro-
apoptotic effects of TGFb1 provides a major escape mechanism
favoring malignancy. For instance, not only the low concentra-
tion of circulating TGFb1, but also the alteration of its signaling
Figure 3. Evaluation of serum levels of TGFb1 and VEGF during colorectal carcinogenesis. The levels of TGFb1 (A) and VEGF (B) were
measured in controls and patient groups (N: control; TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of
adenocarcinoma). TGFb1 and VEGF were detected by ELISA and values expressed as ng/ml and pg/ml serum, respectively (see materials and
methods). A: dots correspond to single TGFb1 values and black lines represent the mean values within the experimental groups. Mean values6 SEM:
N 6.360.4; TA 7.260.45; TVA 6.360.6; IAC 6.960.3; IIAC 4.960.3; IIIAC 4.460.3; IVAC 5.760.5. *Significantly different versus control group (p,0.05). B:
dots correspond to single VEGF values and black lines represent the mean values within the experimental groups. Mean values6 SEM: N 227.0618.7;
TA 215.2631.3; TVA 221.1636.4; IAC 216.3634.4; IIAC 205.0626.6; IIIAC 266.5638.6; IVAC 295.2670.2.
doi:10.1371/journal.pone.0041839.g003
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pathway, may concur in tumor development and progression
[12,15,33]. For this reason, although the stated aim of our study
was to monitor serum inflammation markers during the entire
process of colorectal carcinogenesis, we exploited the availability
of colonic adenoma biopsies to obtain information on the
expression of TGFb1RI and/or TGFb1RII in the benign phase
of the carcinogenic process. Our results are quantitatively
limited, but may well be the first available data of such type.
The semiquantitative immunohistochemical measurement of
TGFb1 receptors in our series of benign colorectal tumor
specimens indicates that derangement of TGFb1RI and/or
TGFb1RII may already be evident at the benign step of colonic
carcinogenesis (Table 1). If this finding is confirmed, it would
mean that the loss of susceptibility to the anti-proliferative effect
of this cytokine is not per se sufficient to explain the shift from
benign to malignant phenotype, and thus other genetic and/or
Table 1. Analysis of the two main TGFb1 receptors in tissue samples of adenomas and adenocarcinomas.
Patients with decreased levels of TGFb1
receptors Type of receptors altered (number of cases)
TGFb1RI TGFb1RII TGFb1RI & TGFb1RII
TA 12/21 (57%) – 4 8
TVA 10/20 (50%) – – 10
IAC 3/5 (60%) 1 2 –
IIAC 5/9 (56%) 1 2 2
IIIAC 7/10 (70%) 2 2 3
IVAC 7/7 (100%) 2 3 2
TGFb1RI: TGFb1 receptor I; TGFb1RII: TGFb1 receptor II.
TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma.
In brackets percentages of patients with alteration of the TGFb1 receptor system. Minimal or low grade immunostaining was taken as an index of receptors’alteration.
doi:10.1371/journal.pone.0041839.t001
Figure 4. Evaluation of serum MMP activity and levels during colorectal carcinogenesis. A: active forms of MMP-2 and MMP-9 are shown
in a representative gelatin zymography. B: MMP-9 activation in the serum was evaluated by densitometric analysis as percentage of active MMP-9
compared to controls (taken as 100%). Dots correspond to the activated MMP-9 value for each subject and black lines represent mean values within
the experimental groups. Mean values 6 SEM: TA 12063.9; TVA 12168.5; IAC 151.63617.2; IIAC 163.81616.6; IIIAC 164.2610.6; IVAC 129.0613.0.
*Significantly different versus control group (p,0.01). C: serum levels of MMP-9 protein were detected by ELISA and expressed as ng/ml serum. Dots
correspond to the MMP-9 value for each subject and black lines represent the mean values within the experimental groups. Mean values 6 SEM: N
1.560.2; TA 1.960.3; TVA 1.960.3; I AC 2.760.3; IIAC 2.860.3; IIIAC 3.060.5; IVAC 2.660.4. *Significantly different versus control group (p,0.05). N:
control; TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma.
doi:10.1371/journal.pone.0041839.g004
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epigenetic alterations would be necessary for the progression to
cancer to occur.
MMP-9 is an enzyme recognized to be primarily involved in
the formation of metastases. Serum levels of MMP-9 were
found to be elevated in many studies on CRC and our results
confirmed those reports [34,35]. The increase of mean serum
levels of MMP-9 (Figure 4B) was statistically significant in stage
III adenocarcinoma patients and was also found to be
significantly correlated with increased serum levels of IL-8 of
CRC at stage III. Thus, serum MMP-9 could be another valid
marker of colorectal cancer progression, especially if combined
with IL-8, (and CRP). Further, immunohistochemical staining of
MMP-9 in CRC specimens showed strong positivity in tumor
cells and confirmed that tumor associated macrophages are
important source of MMPs during the carcinogenic process
(Figure 5).
Analysis of MMP-9 activation in the serum by zymography
provided findings of particular interest. Serum levels of activated
MMP-9 showed a trend that was strikingly similar to that of the
IL-8 (Figure 4A). As found with IL-8, mean serum values of
activated MMP-9 in patients with tubular or tubulovillous
adenomas, as well as those at stage I adenocarcinoma, consistently
remained within the control range. Both parameters only in-
creased significantly from stage II adenocarcinoma onwards.
Thus, if these findings should be confirmed by additional data,
they would indicate that the two different macrophage pheno-
Figure 5. Distribution and expression of MMP-9 on paraffin embedded CRC tissue sections. A: a representative image of carcinoma tissue
at stage III showed strong staining for MMP-9, localized in the cytoplasm of both tumor cells and inflammatory cells (10x/0.22 objective). For
experimental details see materials and methods. B: higher magnification of a MMP-9 positive area of the same cancer section (40x/0.65 objective). The
images were obtained using Digital Microscope DMD Leica, Leica Microsystems, Milan, Italy.
doi:10.1371/journal.pone.0041839.g005
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types, so named M1 and M2, may be present simultaneously in
overt colorectal cancer, rather than there being a distinct switch
from the M1 pro-inflammatory phenotype to the M2 tumor-
promoting phenotype, as in the hypothesis put forth by Mantovani
and Sica [6].
In conclusion, we investigated the trend of blood levels of IL-8,
IL-6, TGFb1, VEGF and MMP-9, throughout the benign to
malignant phases of colorectal neoplastic disease. IL-8 levels and
MMP-9 activity and levels showed very similar trends, increasing
concomitantly and only in patients with established cancer,
starting from stage II adenocarcinoma. An almost identical trend
was exhibited by the common inflammatory marker CRP. These
findings point to the combined quantification of IL-8, MMP-9 and
CRP as a reliable and advanced index of inflammation-related
processes occurring in the malignant phase of colorectal carcino-
genesis. Most likely, all such parameters drop dramatically after
surgical removal of the malignant neoplasia and may rise again in
case of disease’s relapse. Follow-up of the patients recruited in this
study is in progress to confirm this hypothesis and to verify if
a direct correlation exists between IL-8/MMP-9 increased levels
and poor clinical outcome.
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